INNOVATE's MediBeacon receives FDA approval for next-gen TGFR System

INNOVATE Corp.

MediBeacon (44.7%-owned by VATE) gets FDA nod for TGFR System with reusable sensor.
Reusable sensor lowers cost vs prior single-use version; designed for patient comfort.
Initial sales at select US and China academic medical centers expected Q1 2026.
TGFR System featured as lead article in Journal of the American Society of Nephrology August 2025.
Transdermal GFR assessment does not require age, weight, sex, race, or ethnicity inputs.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.